A typical case of eosinophilic granulocytic leukemia with PML-RAR alpha fusion gene expression is reported. The patient achieved complete remission after oral administration of alltrans retinoic acid without any exposure to cytotoxic agents. The facts strongly suggest that the genetic event occurred at the level of pluripotent stem cells. Keywords: leukemia; eosinophilic; PML-RAR alpha; retinoic acid
Introduction
It has been well demonstrated that the presence of a fusion gene, PML-RAR alpha, resulting from the reciprocal translocation of human chromosome 15 and 17, t(15;17)(q22:q21) is a specific molecular marker of acute promyelocytic leukemia, and plays an important role in the pathogenesis of that disease. [1] [2] [3] [4] Until now PML-RAR alpha fusion gene has not been found in other malignant cells. Recently, we saw a typi- PML-RAR alpha fusion gene expression that achieved complete remission after differentiation therapy with all-trans larity with a G/E ratio of 14.1:1. The differential count showed retinoic acid (ATRA). We would like to present it for further 5.1% myeloblasts, 1.0% neutrophilic promyelocytes, 14.5% attention.
eosinophilic promyelocytes, 12.5% eosinophilic myelocytes, 10.0% eosinophilic metamyelocytes, 14.0% eosinophilic band-formed granulocytes and 26.0% eosinophilic-segmented Case history granulocytes. The eosinophilic granules seen on the smear were coarse, refractile, orange-red with slight blue staining Lee XX, a 66-year-old female, was admitted to hospital in and unevenly distributed ( Figure 1 ). In some myeloblasts and December 1991 with complaints of dizziness and chest distress for 2 weeks. On physical examination the patient revealed lassitude and pallor. The superficial lymph nodes were not enlarged. There was definite tenderness on slight pressure on the lower part of the sternum. The liver and spleen were not palpable under the costal margin. No petechia and ecchymosis could be found over the surface of the body.
B-ultrasonic examination showed the size of the liver and spleen was normal.
The analytical test of peripheral blood showed hemoglobin 108 g/l, leukocyte count 64.3 × 10 9 /l, platelet count 192 × 10 9 /l. Cell morphology in peripheral blood films showed 1% eosinophilic metamyelocyte, 13% eosinophilic band-formed granulocytes and 69% eosinophilic-segmented granulocytes.
On bone marrow smear there was pronounced hypercellu- eosinophilic promyelocytes the nuclei were twisted and twisted and folded nuclei. Auer rods could be found in their cytoplasm. On the basis of the above evidence, the diagnosis folded with a fine nuclear chromatin pattern. Auer rods could be found in their cytoplasm. Mitosis of the eosinophils could of acute eosinophilic granulocytic leukemia could be established, and according to the typically morphological feature easily be seen. The proliferation of erythrocytic series was depressed. Part of the erythroblasts underwent megaloblastof the eosinophilic granules in the cytoplasm, acute promyelocytic leukemia could also be ruled out. like transformation. Within the area of 2 × 3 cm of bone marrow smear, 65 megakaryocytes could be found; most of them PML-RAR alpha is a fusion gene resulting from reciprocal translocation of human chromosomes by juxtaposing the PML were granular and platelet-producing. There was an abundant amount of stainable iron in the histiocytes of the bone gene on chromosome 15 and the RAR alpha gene on chromosome 17. It plays a key role in the pathogenesis of acute promarrow.
Three days after admission ATRA therapy started 30 mg myelocytic leukemia and is also a specific molecular marker which has not been found in other malignancies. orally every 6 h. Ten days later the leukocyte count of peripheral blood dropped from 64.3 × 10 9 /l to 44.5 × 10 9 /l, the plateHere, interestingly enough, PML-RAR alpha fusion gene was unequivocally detected from both peripheral blood and let count rose from 192 × 10 9 /l to 332 × 10 9 /l. Eosinophilic granulocytes in the differential count decreased from 83 to bone marrow in a typical case of acute eosinophilic granulocytic leukemia that achieved complete remission after oral 64%. Twenty days after treatment tenderness of the sternum disappeared. Then, there was a gradual but steady decrease administration of ATRA without any exposure to cytotoxic agents. Owing to the blank control and normal control repeatin the leukocyte count and percentage of eosinophils in the peripheral blood. Seventy days after treatment, bone marrow edly being negative, the possibility of contamination could be excluded. In addition, the detection of RAR alpha-PML tranexamination showed the cellularity had returned to normal with a G/E ratio of 3.52:1, eosinophilic promyelocytes script indicated that the abnormality of chromosomes was a reciprocal or a balanced translocation. Recently, Takatsuki et decreased from 14.5 to 0.5%, eosinophilic myelocytes and metamyelocytes fell from 12.5 and 10.0% to 1.5%, eosinoal 6 found that PML-RAR alpha presented not only in CFU-GM, but also in BFU-E. Altogether, these facts strongly suggest that philic band-formed granulocytes decreased from 14.0 to 2.5%, and eosinophilic-segmented granulocytes from 26.0 to the formation of PML-RAR alpha fusion gene occurs at the developmental stage prior to the progenitor cell for promyelo-15%. Auer rods could no longer be found. One hundred and three days after continuous oral administration of ATRA, the cyte, namely at the level of pluripotent stem cells. 7 In the main, transformed cells developed into an acute promyeloperipheral blood and bone marrow achieved complete remission. Next, three intensive courses of DAH protocol cytic leukemia, but in certain situations they could also advance toward acute eosinophilic leukemia, although the (daunorubicin, cytosine arabinoside, harringtonine) were given for consolidation.
precise mechanism of distinct differentiation remains to be elucidated. In June 1995, the patient was quite well with a hemoglobin concentration of 121 g/l, leukocyte count of 4.4 × 10 9 /l and The dosage of ATRA given to the patient was 30 mg every 6 h. It corresponded to 68 mg/m 2 and was much higher than platelet count of 200 × 10 9 /l. The differential count of leukocytes in the periperhal blood was normal with 1.0% eosinothe usual dose. The reason for doing so was that at the beginning we were really not certain if ATRA would work in that philic-segmented granulocytes. Bone marrow examination showed normal cellularity with a G/E ratio of 3.51:1. The particular case. To our surprise, that patient not only responded but did not even show hyperleukocytosis at day nucleated cells in all series were proportionally and morphologically normal.
10-20 after ATRA treatment. Individual discrepancy might play a role in that situation. Another important possibility was Cytogenic study showed 46,XX. However, owing to the unsatisfactory preparation of chromosome, no numerical and that most of the abnormal cells in the bone marrow and peripheral blood were relatively well differentiated, therefore structural abnormality of chromosome could be found with G banding analysis. they might not be prone to further division. Total RNAs were extracted from the peripheral blood and bone marrow using a one-step guanidine-thiocyanate-phenolchloroform method.
References RT-PCR was performed according to the procedures in our centage of myeloblasts was higher than 5%. Some of the mye- Figure 2 ). Southern blot analysis lymphoma.
1,2 Here, we report a case of atypical chronic on DNA restricted with BamHI and BglII and hybridized to a myeloid leukemia (CML) in blastic transformation in which large M-BCR probe revealed a germline configuration of the cytogenetic analysis showed the clonal abnormality of BCR gene. Chemotherapy was started but, unfortunately, the t(2;8)(p12;q24).
patient ran a rapid downhill course and a computed tomog-A 51-year-old man was admitted for fever and headache.
ram of brain showed multiple contrast-enhanced cerebral Physical examination showed pallor and massive hepatolesions. He succumbed on the 3rd day of hospitalization and splenomegaly. Complete blood counts revealed: hemoglobin a post-mortem examination was not performed. 6.7 g/dl, leucocyte count 451 × 10 9 /l (differential: blasts 23%, Our case confirms that, at the cytogenetic level, the translopromyelocytes 20%, myelocytes 16%, neutrophils 33%, lymcations associated with Burkitt's lymphoma can be present in phocytes 2% and monocytes 6%) and platelet count non-B lineage hematologic malignancies. The clinical and 89 × 10 9 /l. Dysplastic changes were noted in neutrophils and hematologic findings in our case are in keeping with a diagmonocytes ( Figure 1 ). There was no basophilia. The marrow nosis of atypical CML in myeloblastic transformation. Atypical was markedly hypercellular with increased blasts of myeloid CML, which is classified by the French-American-British morphology accounting for 37% of all nucleated cells. GranuGroup as one of the chronic myleoid leukemias, 3 has features locytic maturation was evident but dysplastic. Megakaryoof a myelodysplastic syndrome as well as a myeloproliferative cytes were adequately present though erythropoiesis was sevdisorder. These cases lack the Ph chromosome and the BCR erely depressed. No ringed sideroblasts were found.
gene is not rearranged. In a series of 10 such patients studied, Cytochemically, the blast cells were positive for myeloperoxifive (50%) had clonal cytogenetic abnormality either on presdase and Sudan black B. Immunophenotyping on marrow entation or follow-up. 4 Loss of the Y chromosome, which was noted in our patient in addition to t(2;8), is also a well documented feature in acute myeloid leukemia both as the only karyotypic abnormality or as a secondary change. 5 Another well recognized Burkitt translocation, t(8;14) (q24;q32), has also been reported in a case of CD8 + large granular lymphocyte leukemia, 6 one of the mature T cell malignancies. 7 Owing to the lack of material, it was not possible to examine for rearrangements of c-myc and immunoglobulin -light chain loci in our case with t(2;8)(p12;q24). It is important to correlate the findings from a larger series of patients with atypical CML to see if there is any consistent karyotypic abnormality in this recently defined entity.
Figure 1
Peripheral blood smear showing circulating blasts, immature granulocytes, two dysplastic neutrophils -cytoplasmic hypogranulation (thick arrow) and abnormal nuclear segmentation (thin arrow), and a dysplastic monocyte (arrowhead). Wright-Giemsa × 1000. calf swelling to be a haematoma; he also had a right retinal interferon-␣ haemorrhage and splenomegaly palpable 4 cm below the costal margin. There were several subcutaneous nodules over both thighs and biopsy showed these were leukaemic Introduction infiltrates. Further investigation showed: haemoglobin 8.6 g/dl, white Chronic myeloid leukaemia (CML) is characterised in most blood cell count 230 × 10 9 /l (blasts 9.6 × 10 9 /l), platelets cases by the presence of the Philadelphia chromosome, a 118 × 10 9 /l. Prothrombin time, kaolin cephalin clotting time, translocation between chromosomes 9 and 22. The resulting thrombin time and bleeding time were all within the normal fusion of bcr and abl genes results in production of a chimeric range. Bone marrow aspirate was dry and an adequate tre-210 kDa protein with tyrosine kinase activity that may play a phine was not obtained. Cytogenetic analysis of peripheral part in the disordered stem cell growth of CML. The median blood cells showed 11/11 metaphases contained the Philadelsurvival for this condition has lengthened from 3 years to more phia chromosome translocation, t(9;22)(q34;q11). recent estimates of 5 to 6 years. 1 Following initial leukopheresis busulphan was introduced Chemotherapy has been the mainstay of treatment for the and continued to February 1989 at which time the splenomegdisease. 1, 2 More recently it has become clear that interferon aly had resolved. A sibling bone marrow donor could not be alpha (IFN-␣) is effective in the induction of both haematologifound, so in April 1989 he was entered into the Medical cal and cytogenetic remission. 3 The mechanism of IFN-␣ in Research Council CML 3 study, at which time his bone mar-CML is unclear but antiproliferative and immunomodulatory row aspirate was hypercellular with an M:E ratio of 7:1; metaeffects may be involved. It is likely that achievement of cytomyelocytes 30%, myelocytes 16%, promyelocytes 9%, blasts genetic response equates with reduction in the leukaemic 1%. Cytogenetic examination of marrow cells showed 30/30 clone and that a complete cytogenetic response might thereto be Ph′ positive. Busulphan 4 mg daily was continued until fore be expected to give the best chance of long-term survival the white cell count was reduced to less than 20 × 10 9 /l, at or even cure. The most sensitive index of the disease uses the which time (June 1989) human lymphoblastoid IFN-␣ polymerase chain reaction (PCR) to detect and quantitate bcr-(Wellferon; Glaxo Wellcome, UK) was started at a dose of 3 abl transcripts. Most patients who achieve complete cytomegaU daily (indicated in Table 1 ). Subsequent dosing with genetic remission remain PCR positive but the levels of interferon was limited by thrombocytopenia such that he was residual bcr-abl transcripts may differ by as much as four receiving as little as 10.5 megaU weekly when his platelet orders of magnitude. 4, 5 count reached a nadir of 37 × 10 9 /l after 48 months of IFN-␣. Numerous studies have employed different IFN-␣ dosage Despite minor toxicity including 'flu-like symptoms and some strategies and have reported a variable incidence of cytomood effects IFN-␣ was not stopped at any stage. genetic response, varying rapidity of response and differing Bone marrow aspirates were obtained at 6 monthly intervals effects on survival. 3, [6] [7] [8] [9] [10] [11] However, despite indications that for morphological and cytogenetic assessment. Table 1 rec-IFN-␣ may enhance survival even without a cytogenetic ords the course of his treatment and the first appearance of response, 6 absence of an early reduction in Ph′ positive metaPh′ negative metaphases at 53 months from the start of IFNphases has been thought to make an eventual complete ␣ therapy. This was followed by further reductions in Ph′ positive cells until a complete cytogenetic remission (CCyR) at 84 months from diagnosis (76 months from starting interferon).
With the improvement in the cytogenetic findings there was
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increasing haematological tolerance for IFN-␣ and he now tolerates 42 megaU weekly with neutrophil counts above was achieved at 6 weeks and for cytogenetic non-responders further dose escalation occurred at 8 months. At 14 months, 1 × 10 9 /l and platelets above 100 × 10 9 /l. Early in the treatment a clone of cells with an additional t(8;21)(q22;q22) was however, non-responders had the IFN-␣ dose reduced to 9 megaU per week. They observed that 9% of first CyR did not identified but this had disappeared after 24 months of IFN-␣ therapy.
occur until 14-24 months of IFN-␣ treatment and that the maximal CyR was not seen until 60 months in two out of 17 Analysis of peripheral blood by the polymerase chain reaction identified this patient as having b2a2 and b3a2 bcr-abl patients achieving CCyR. The authors speculated whether the CyR rate would have been better if the cytogenetic non-RNA products. Semi-quantitative assay of the bcr-abl RNA 12 was performed and the results are tabulated in Table 2 which responders had continued to receive maximum tolerated doses of IFN-␣ -as occurred in our patient. Median survival demonstrates a fall in numbers of bcr-abl transcripts to levels compatible with a CCyR. 4, 5 in the IFN group was 72 months, significantly better than the chemotherapy group.
The randomised German CML study 9 compared chemotherapy (hydroxyurea or busulphan) with IFN-␣, escalating Discussion from a starting dose of 5 megaU/m 2 /day. The IFN arm achieved a CyR rate of 18%, a CCyR of 7.2% and the longest IFN-␣ treatment produces a complete haematological response in 30-80% of cases and major cytogenetic responses reported interval to CCyR was 30 months. The interval to first CyR is not reported. Although there was a trend for improved (less than 35% metaphases Ph′ positive) in 10-40% of patients. 1, 2 In their non-randomized study the CALGB group 7 survival in cytogenetic responders compared to nonresponders, this was not significant. In the MD Anderson used an IFN-␣ dose of 5 megaU/m 2 daily and reported a first cytogenetic response (CyR) at a median time of 9 months in study 10 using 5 megaU/m 2 IFN-␣ daily, the CyR rate was 58% and the CCyR rate 26% at a median of 16 months though with 40% of evaluable cases. CCyR was obtained in 18% of cases at a median time of 9 months. They found that in some a wide range of 3-70 months. Some of these patients also received IFN-gamma or hydroxyurea. The median survival patients cytogenetic responses were slow to develop and 5% of CyR were beyond 18 months of treatment, progressing to was 89 months and was significantly longer in those achieving CCyR at up to 24 months. The latest CyR occurred after 40 a CyR. This single centre study suggests that high CyR rates months of treatment. The randomised study of the Italian Comay be achieved by consistent and aggressive dosing with operative Study Group 8 compared chemotherapy with a IFN-␣ which might be difficult to maintain in multicentre studregime of escalating IFN-␣ dosage. A dose of 9 megaU daily ies. Factors associated with major cytogenetic response were the presence at diagnosis of good performance status, being asymptomatic, having a small spleen, high haemoglobin, low CyR rate of 22% (half of which were major or complete). Earliest CyR were seen at a median of 32 weeks and the longest treatment interval to response (other than our patient) was 108 References weeks. 6 There was no significant difference between the median received doses for non-responders and those with any of complete cytogenetic remission.
LETTER TO THE EDITOR
Association between b3a2 BCR/ABL fusion and chronic myeloid leukemia with thrombocythemic onset: fortuitous or real?
Cervantes et al 1 recently reported six cases of chronic myeloid could be associated with a given BCR/ABL fusion. These conflicting findings underline the problems of ascribing clinical leukemia with a thrombocythemic onset. These cases resembled essential thrombocythemia on presentation, with characteristics to particular BCR/ABL fusion junctions, a subject that has received much current attention. 7 platelet counts Ͼ1000 × 10 9 /l, and moderate increases in white cell counts (Ͻ20 × 10 9 /l). With molecular analysis, five Recently, it has been shown that minute amounts of BCR/ABL can be detected in normal individuals who do not of six cases showed a b3a2 BCR/ABL fusion, and only one showed a b2a2 fusion. Cervantes et al regarded these cases have leukemia. 8 Therefore, it appears that while BCR/ABL may confer a proliferative advantage on a pluripotential stem as another form of CML, and suggested that there was an association between b3a2 fusion and CML with thrombocell, additional genetic lesions may be needed for the development of CML. Indeed, the acquisition of additional genetic cythemia.
CML in chronic phase may present with hyperplasia of any lesions also underlies the development of the accelerated and blastic phases of CML. As the malignant phenotypes in leukeor all of the erythroid, granulocytic and megakaryocytic lineages, thereby mimicking other myeloproliferative disorders. mia are largely determined by genetic alterations, 9 the mutation(s) giving rise to a predominant granulocytic hyperFor this reason, the diagnosis of essential thrombocythemia (ET) requires the exclusion of the Philadelphia (Ph) transloplasia and a predominant megakaryocytic hyperplasia may be different, although in both forms BCR/ABL fusion is involved cation t(9;22)(q34;q11), 2 as ET with t(9;22) has a clinical course similar to that of CML, and should receive similar treatas the initiating event. Therefore, instead of simply regarding thrombocythemia with BCR/ABL as another facet of CML, ment.
We have encountered five patients with apparent ET further investigations of these cases may disclose putative genetic alterations that may contribute to our understanding of (platelet counts 1100, 2400, 2460, 2700 and 3200 × 10 9 /l) who were found to be BCR/ABL positive (three of them had the progression of the BCR/ABL clone, as well as factors controlling megakaryocytic differentiation. been reported previously). 3 Karyotypic analysis showed that three cases had 100% Ph-positive metaphases on presenNevertheless, it is imperative that discussions on the underlying genetic lesions in BCR/ABL-positive thrombocythemia tation, one case had 66% Ph-positive and 33% normal metaphases, and one case had normal metaphases only. On molshould not distract us from the important issue, as pointed out by Cervantes et al and many other groups, [10] [11] [12] [13] [14] that these ecular analysis by reverse transcription polymerase chain reaction, three patients showed a b3a2 BCR/ABL fusion, while patients have a disease with a clinical course very similar to CML. Therefore, they should receive treatment strategies two showed a b2a2 fusion. It is noteworthy that one case was karyotypically normal, underlying the importance of molecuidentical to those of CML. lar investigations for BCR/ABL in thrombocythemia. Secondly, one case had 33% normal metaphases on presentation, an YL Kwong University Department of Medicine, Professorial Block unusual finding with reference to CML in chronic phase.
Although the number of cases of thrombocythemia with Queen Mary Hospital Pokfulam Road BCR/ABL reported were small and a definitive conclusion cannot be drawn, it may be, contrary to the suggestion of CervHong Kong antes et al, that the association between b3a2 BCR/ABL fusion and thrombocythemia is fortuitous. As b3a2 and b2a2 fusions were more or less equally as frequent in CML, 4 and most of References these cases presented with granulocytic hyperplasia instead of simply high platelet counts, it is unlikely that b3a2 per se can
